Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Operating Expenses (2020 - 2025)

Roivant Sciences' Operating Expenses history spans 6 years, with the latest figure at $341.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 20.38% year-over-year to $341.2 million; the TTM value through Dec 2025 reached $936.0 million, up 10.1%, while the annual FY2025 figure was $1.1 billion, 29.26% up from the prior year.
  • Operating Expenses reached $341.2 million in Q4 2025 per ROIV's latest filing, up from $307.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $698.4 million in Q3 2021 to a low of $162.1 million in Q2 2021.
  • Average Operating Expenses over 5 years is $309.6 million, with a median of $287.1 million recorded in 2025.
  • Peak YoY movement for Operating Expenses: surged 342.42% in 2021, then plummeted 58.01% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $270.4 million in 2021, then skyrocketed by 46.15% to $395.1 million in 2022, then plummeted by 40.14% to $236.5 million in 2023, then rose by 19.82% to $283.4 million in 2024, then increased by 20.38% to $341.2 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Operating Expenses are $341.2 million (Q4 2025), $307.8 million (Q3 2025), and $287.1 million (Q2 2025).